The Profile of Heparanase Expression Distinguishes Differentiated Thyroid Carcinoma from Benign Neoplasms

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Oct 22

PMID 26488476

Citations 12

Authors

Leandro Luongo Matos

Eloah Rabello Suarez

Therese Rachell Theodoro

Damila Cristina Trufelli

Carina Mucciolo Melo

Larissa Ferraz Garcia

Olivia Capela Grimaldi Oliveira

Maria Graciela Luongo Matos

Jossi Ledo Kanda

Helena Bonciani Nader

Joao Roberto Maciel Martins

Maria Aparecida Silva Pinhal

Affiliations

Soon will be listed here.

Abstract

Introduction: The search for a specific marker that could help to distinguish between differentiated thyroid carcinoma and benign lesions remains elusive in clinical practice. Heparanase (HPSE) is an endo-beta-glucoronidase implicated in the process of tumor invasion, and the heparanase-2 (HPSE2) modulates HPSE activity. The aim of this study was to evaluate the role of heparanases in the development and differential diagnosis of follicular pattern thyroid lesions.

Methods: HPSE and HPSE2 expression by qRT-PCR, immunohistochemistry evaluation, western blot analysis and HPSE enzymatic activity were evaluated.

Results: The expression of heparanases by qRT-PCR showed an increase of HPSE2 in thyroid carcinoma (P = 0.001). HPSE activity was found to be higher in the malignant neoplasms than in the benign tumors (P<0.0001). On Western blot analysis, HPSE2 isoforms were detected only in malignant tumors. The immunohistochemical assay allowed us to establish a distinct pattern for malignant and benign tumors. Carcinomas showed a typical combination of positive labeling for neoplastic cells and negative immunostaining in colloid, when compared to benign tumors (P<0.0001). The proposed diagnostic test presents sensitivity and negative predictive value of around 100%, showing itself to be an accurate test for distinguishing between malignant and benign lesions.

Conclusions: This study shows, for the first time, a distinct profile of HPSE expression in thyroid carcinoma suggesting its role in carcinogenesis.

Citing Articles

Heparanase 2 Modulation Inhibits HSV-2 Replication by Regulating Heparan Sulfate.

Hopkins J, Volety I, Qatanani F, Shukla D Viruses. 2025; 16(12.

PMID: 39772142 PMC: 11680312. DOI: 10.3390/v16121832.

MicroRNA-219a-2-3p modulates the proliferation of thyroid cancer cells via the HPSE/cyclin D1 pathway.

Yang C, Zhang S, Chang X, Huang Y, Cui D, Liu Z Exp Ther Med. 2021; 21(6):659.

PMID: 33968189 PMC: 8097191. DOI: 10.3892/etm.2021.10091.

A Pro-Tumorigenic Effect of Heparanase 2 (Hpa2) in Thyroid Carcinoma Involves Its Localization to the Nuclear Membrane.

Margulis I, Naroditsky I, Gross-Cohen M, Ilan N, Vlodavsky I, Doweck I Front Oncol. 2021; 11:645524.

PMID: 33959505 PMC: 8093622. DOI: 10.3389/fonc.2021.645524.

Heparanase modulation by Wingless/INT (Wnt).

Melo C, Nader H, Justo G, Pinhal M Mol Biol Rep. 2021; 48(4):3117-3125.

PMID: 33891270 DOI: 10.1007/s11033-021-06348-3.

Heparanase and the hallmarks of cancer.

Jayatilleke K, Hulett M J Transl Med. 2020; 18(1):453.

PMID: 33256730 PMC: 7706218. DOI: 10.1186/s12967-020-02624-1.

References

Lu S, Huang M, Kobayashi Y, Komiyama A, Li X, Katoh R . Alterations of basement membrane in di-isopropanolnitrosamine-induced carcinogenesis of the rat thyroid gland: an immunohistochemical study. Virchows Arch. 2000; 436(6):595-601. DOI: 10.1007/s004280000180. View

Weyl Ben Arush M, Shafat I, Shafat I, Ben Barak A, Shalom R, Vlodavsky I . Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study. Pediatr Hematol Oncol. 2009; 26(4):157-64. DOI: 10.1080/08880010902754917. View

Conejo J, Kleeff J, Koliopanos A, Matsuda K, Zhu Z, GOECKE H . Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000; 88(1):12-20. DOI: 10.1002/1097-0215(20001001)88:1<12::aid-ijc3>3.0.co;2-t. View

McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R . Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun. 2000; 276(3):1170-7. DOI: 10.1006/bbrc.2000.3586. View

Jiang P, Kumar A, Parrillo J, Dempsey L, Platt J, Prinz R . Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem. 2002; 277(11):8989-98. DOI: 10.1074/jbc.M105682200. View

Alexander E, Kennedy G, Baloch Z, Cibas E, Chudova D, Diggans J . Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012; 367(8):705-15. DOI: 10.1056/NEJMoa1203208. View

Matos L, Giglio A, Matsubayashi C, Farah M, Del Giglio A, da Silva Pinhal M . Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012; 7:97. PMC: 3523001. DOI: 10.1186/1746-1596-7-97. View

Hodak S, Rosenthal D . Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid. 2012; 23(2):131-4. DOI: 10.1089/thy.2012.0320. View

Thompson C, Purushothaman A, Ramani V, Vlodavsky I, Sanderson R . Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013; 288(14):10093-10099. PMC: 3617250. DOI: 10.1074/jbc.C112.444562. View

10.

Reis Rodrigues L, Oliveira L, da Silva Pinhal M . Expression of heparanase isoforms in intervertebral discs classified according to Pfirrmann grading system for disc degeneration. Spine (Phila Pa 1976). 2013; 38(13):1112-8. DOI: 10.1097/BRS.0b013e3182894cf4. View

11.

Suarez E, Paredes-Gamero E, Del Giglio A, Tersariol I, Nader H, Pinhal M . Heparan sulfate mediates trastuzumab effect in breast cancer cells. BMC Cancer. 2013; 13:444. PMC: 3850728. DOI: 10.1186/1471-2407-13-444. View

12.

Zhang X, Xu S, Tan Q, Liu L . High expression of heparanase-2 is an independent prognostic parameter for favorable survival in gastric cancer patients. Cancer Epidemiol. 2013; 37(6):1010-3. DOI: 10.1016/j.canep.2013.09.012. View

13.

Dempsey L, Brunn G, Platt J . Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci. 2000; 25(8):349-51. DOI: 10.1016/s0968-0004(00)01619-4. View

14.

Nadav L, Eldor A, Yacoby-Zeevi O, Zamir E, Pecker I, Ilan N . Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci. 2002; 115(Pt 10):2179-87. DOI: 10.1242/jcs.115.10.2179. View

15.

Linke M, Herzog V, Brix K . Trafficking of lysosomal cathepsin B-green fluorescent protein to the surface of thyroid epithelial cells involves the endosomal/lysosomal compartment. J Cell Sci. 2002; 115(Pt 24):4877-89. DOI: 10.1242/jcs.00184. View

16.

Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K . Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology. 2003; 43(2):157-64. DOI: 10.1046/j.1365-2559.2003.01656.x. View

17.

Behzad F, Brenchley P . A multiwell format assay for heparanase. Anal Biochem. 2003; 320(2):207-13. DOI: 10.1016/s0003-2697(03)00358-0. View

18.

Buchs A, Zehavi S, Sher O, Yeheskely E, Muggia-Sulam M, Sherman Y . Heparanase, galectin-3, and tissue factor mRNA are expressed in benign neoplasms of the thyroid. Endocrine. 2003; 22(2):81-4. DOI: 10.1385/ENDO:22:2:81. View

19.

Xu X, Quiros R, Maxhimer J, Jiang P, Marcinek R, Ain K . Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res. 2003; 9(16 Pt 1):5968-79. View

20.

Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S . Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci. 2004; 117(Pt 11):2249-58. DOI: 10.1242/jcs.01068. View